Provided by Tiger Fintech (Singapore) Pte. Ltd.

Royalty Pharma plc

31.11
-0.6800-2.14%
Post-market: 31.00-0.1100-0.35%19:43 EDT
Volume:7.27M
Turnover:224.94M
Market Cap:13.47B
PE:16.27
High:31.70
Open:31.30
Low:30.45
Close:31.79
Loading ...

Bank of America Securities Remains a Buy on Royalty Pharma (RPRX)

TIPRANKS
·
27 Mar

BRIEF-Royalty Pharma Announces Upcoming Investor Day

Reuters
·
27 Mar

Royalty Pharma Announces Upcoming Investor Day

THOMSON REUTERS
·
27 Mar

TD Cowen Reaffirms Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
27 Mar

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

StockStory
·
21 Mar

Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Simply Wall St.
·
19 Mar

Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey
·
24 Feb

Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition

TIPRANKS
·
13 Feb

BUZZ-Royalty Pharma falls after investing $250 mln in Biogen's lupus treatment

Reuters
·
12 Feb

Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D

MT Newswires Live
·
12 Feb

Royalty Pharma announces R&D funding collaboration with Biogen

TIPRANKS
·
12 Feb

Royalty Pharma : Litifilimab Is Currently in Phase 3 Trials for Both Sle and Cle With Results Expected Between 2026 and 2027

THOMSON REUTERS
·
12 Feb

Royalty Pharma Announces R&D Funding Collaboration With Biogen

THOMSON REUTERS
·
12 Feb

Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

GuruFocus.com
·
12 Feb

Royalty Pharma PLC reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Feb

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
11 Feb

Royalty Pharma Q4 Net Income, Revenue Decrease

MT Newswires Live
·
11 Feb

Royalty Pharma Expects 2025 Portfolio Receipts Of $2.9B-$3.05B, With Operating And Professional Costs Of Approximately 10% Of Portfolio Receipts And Interest Paid Of $260M

Benzinga
·
11 Feb

Earnings Flash (RPRX) Royalty Pharma Posts Q4 Net Income $208 Million

MT Newswires Live
·
11 Feb

Royalty Pharma Q4 2024 Adj EPS $1.16 Beats $1.05 Estimate, Sales $594.00M Miss $678.89M Estimate

Benzinga
·
11 Feb